Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Jagadish Bilgi

Pediatrics Ankeny, IA Medical Doctor

NPI 1891803102 CMS profile 872481

2201 W 1St St, Ankeny, IA 50023

Open in the dashboard

General payments

$953

55 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Jagadish Bilgi of Ankeny, IA is reported in the CMS Open Payments database as having received $953 across 55 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $232 13
2021 General $249 15
2020 General $237 14
2019 General $235 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jagadish Bilgi
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Jagadish Bilgi were reported at $0. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Jagadish Bilgi Pediatrics median Middle half National median
2019 $235 $86 $31–$183 $163
2020 $237 $49 $22–$110 $114
2021 $249 $68 $27–$158 $132
2022 $232 $77 $30–$173 $149
2023 $0 $88 $33–$190 $160
2024 $0 $94 $34–$206 $164
2025 $0 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AstraZeneca Pharmaceuticals LP $146 7 payments
  2. Ironshore Pharmaceuticals Inc. $130 6 payments
  3. Tris Pharma Inc $109 6 payments
  4. Supernus Pharmaceuticals, Inc. $108 6 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $99 6 payments
  6. Adlon Therapeutics L.P. $83 5 payments
  7. GlaxoSmithKline, LLC. $72 6 payments
  8. Shire North American Group Inc $51 3 payments
  9. Neos Therapeutics, LP $37 2 payments
  10. Corium, Inc. $35 2 payments
  11. Other $82 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $953 55 payments
Products named General payments · program years 2019–2022
  1. VYVANSE $136 8 payments
  2. FASENRA $122 6 payments
  3. QELBREE $108 6 payments
  4. ADHANSIA XR $83 5 payments
  5. Jornay PM 20mg capsules (Bottle of 100) $74 3 payments
  6. Quillichew ER $70 4 payments
  7. JORNAY PM $56 3 payments
  8. NUCALA $47 4 payments
  9. Quillivant XR $39 2 payments
  10. Azstarys $35 2 payments
  11. Other $218 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

55 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record